Skip to main content

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

Written by Customer Service on . Posted in Public Companies.

Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing.

ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee health testing. Psychemedics was selected for its exceptional performance, industry leadership, and dedication to delivering reliable and accurate testing services.

“We are honored to be recognized as one of the Top 10 Employee Health Testing Services Providers,” said Brian Hullinger, Chief Executive Officer and President of Psychemedics Corporation. “This achievement is a testament to our unwavering commitment to providing high-quality, innovative solutions for drug testing.”

Psychemedics’ patented hair analysis technology offers a non-invasive and highly accurate method for detecting drug use over an extended period, providing employers with valuable insights into their employees’ health and well-being. With over 30 years of experience, Psychemedics has helped thousands of companies worldwide maintain safe and drug-free workplaces.

For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit https://www.psychemedics.com.

About Psychemedics 

Psychemedics Corporation (NASDAQ: PMD) is a leading global provider of innovative hair testing for drugs of abuse. With over 30 years of experience, Psychemedics has pioneered the science of hair testing and provides clients with the most accurate and reliable hair drug test results in the industry. The company’s patented technology is used by thousands of companies worldwide to screen applicants and employees for drug use, helping to create safer and more productive workplaces.

Investor Relations:
Phone: 978-206-8220
Email: InvestorRelations@psychemedics.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.